NXTC NextCure, Inc.
Mergers ·
NextCure (Nasdaq: NXTC) agreed to an all-stock merger with Avere Therapeutics. The 8-K puts pre-merger Avere holders at about 98.11% of the combined company, which would take the Avere Therapeutics name.
NextCure agreed to pay Hainan Simcere Zaiming $17 million, including a $12 million upfront payment, for rights to a Phase 1 antibody drug conjugate. A Zaiming affiliate agreed to buy 4,063,633 shares for $2.0 million, and the company now says its cash lasts into mid-2026, not the second half of 2026 that its March 6 annual report gave.
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on cancer patients whose disease does not respond to, or progresses on, current therapies. It advances targeted therapies, including antibody-drug conjugates (ADCs), which consist of a monoclonal antibody conjugated to a cytotoxic drug through a chemical linker. Its product candidate SIM0505 was licensed from Simcere Zaiming Pharmaceutical Co., Ltd., and is an ADC directed to cadherin-6 (CDH6) that carries a topoisomerase 1 inhibitor payload. Simcere Zaiming retains rights in China, Hong Kong, Macau and Taiwan. SIM0505 is in Phase 1 dose escalation studies in China for solid tumors, including ovarian, endometrial, non-small cell lung and renal cancers. The FDA cleared an Investigational New Drug application for a Phase 1 trial in December 2024, and the IND was assigned to NextCure in June 2025. The company announced dosing its first patient in October 2025 and expects to provide a Phase 1 dose escalation data readout in the second quarter of 2026. Its second product, LNCB74, is a B7-H4 targeted ADC designed to kill tumors, and preclinical studies demonstrated potent tumor killing and a favorable safety profile.
| Product or program | What it is | Stage |
|---|---|---|
| SIM0505 | CDH6-directed ADC with topoisomerase 1 inhibitor payload for solid tumors | Phase 1 dose escalation (China); first US patient dosed October 2025 |
| LNCB74 | B7-H4 targeted antibody-drug conjugate for tumors |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $44.9 million | $41.5 million |
| Net income (loss) | -$55.8 million | -$55.7 million |
| Cash from operations | -$49.6 million | -$40.8 million |
| Cash and equivalents | $26.0 million | $27.7 million |
Our latest story on this, dated Jul 14, 2026: "NextCure signs merger agreement with Avere Therapeutics alongside $320 million private placement". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 14, 2026: "NextCure signs merger agreement with Avere Therapeutics alongside $320 million private placement". The story links the filing or release it is based on. Read the story.
NextCure, Inc. trades under the ticker NXTC on NASDAQ.
NextCure, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for NextCure, Inc. is 1661059. Its filings are on SEC EDGAR.
4,577,359 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Our directory records NextCure, Inc. under United States.
Our directory classifies NextCure, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for NextCure, Inc. is US65343E2072.
aibio.space lists NextCure, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on cancer patients whose disease does not respond to, or progresses on, current therapies. It advances targeted therapies, including antibody-drug conjugates (ADCs), which consist of a monoclonal antibody conjugated to a cytotoxic drug through a chemical linker.
SIM0505: CDH6-directed ADC with topoisomerase 1 inhibitor payload for solid tumors Stage: Phase 1 dose escalation (China); first US patient dosed October 2025.
LNCB74: B7-H4 targeted antibody-drug conjugate for tumors Stage: not stated in text.
NextCure, Inc. reported a net loss of $55.8 million for the fiscal year ended Dec 31, 2025, and used $49.6 million of cash in operations, per its annual report to the SEC.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 1.01,2.05,5.01,5.02,7.01,8.01,9.01). Source
Filed documents for a merger or acquisition. SEC Form 425. Source
Reported a financing. SEC Form 424B1. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 8.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio